Surgical treatment of 32 patients with peripheral intrahepatic cholangiocarcinoma

Author:

Harrison L E1,Fong Y1,Klimstra D S2,Zee S Y2,Blumgart L H1

Affiliation:

1. Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA

2. Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA

Abstract

Abstract Background Peripheral intrahepatic cholangiocarcinoma (PIC) is an intrahepatic primary liver neoplasm which is clinicopathologically distinct from hepatocellular carcinoma and major duct cholangiocarcinoma. The clinical outcome after resection of these rare tumours is not well documented. Methods Review of the hepatic database and tumour registry at Memorial Sloan-Kettering Cancer Center identified 32 cases of PIC resected for cure over a 23-year period. Intrahepatic cholangiocarcinomas with major bile duct involvement were excluded from this analysis. Demographics, pathological features, biochemical markers, operative results and survival were analysed. Results The majority of patients presented with abdominal pain (n = 19). Only two patients had pathological evidence of hepatic cirrhosis. Serum marker levels included α-fetoprotein (AFP; median 3·7 (range 0–225) ng/ml) and carcinoembryonic antigen (CEA; median 1·6 (range 0–30) ng/ml). Type of hepatic resection included: wedge (n = 2), lobectomy (n = 14) and extended lobectomy (n = 16). There was one postoperative death. Median follow-up time was 27 months. Median survival was 59 months with an actuarial 5-year survival of 42 per cent. Vascular invasion and intrahepatic satellite lesions were predictors of worse survival (P < 0·05). Conclusion PIC is a rare hepatic primary tumour, which usually presents in non-cirrhotic livers with a normal serum AFP and CEA level. In selected patients, complete surgical resection can be performed safely and is associated with long-term survival.

Publisher

Oxford University Press (OUP)

Subject

Surgery

Cited by 62 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Current standards and future perspectives in adjuvant treatment for biliary tract cancers;Cancer Treatment Reviews;2020-03

2. Biology of Disease and Prognostic Factors of Cholangiocarcinomas;Tumors and Tumor-Like Lesions of the Hepatobiliary Tract;2016-10-20

3. Multimodality treatment of intrahepatic cholangiocarcinoma: A review;Journal of Surgical Oncology;2016-01

4. Biology of Disease and Prognostic Factors of Cholangiocarcinomas;Tumors and Tumor-Like Lesions of the Hepatobiliary Tract;2016

5. Surgical treatment for intrahepatic cholangiocarcinoma in Europe: a single center experience;Journal of Hepato-Biliary-Pancreatic Sciences;2014-08-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3